Hormone-Refractory Prostate Cancer Completed Phase 2 Trials for Dovitinib (DB05928)

Also known as: Hormone Refractory Prostate Cancer Disease / Hormone Refractory Prostate Cancer / Castration-resistant prostate cancer / Hormone refractory prostate cancer (disorder)

IndicationStatusPhase
DBCOND0030169 (Hormone-Refractory Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01741116Dovitinib(TKI258) in Patients With Castration-resistant Prostate CancerTreatment